The focus of the Data Management & Biostatistics Core is the acquisition of data, data management, review and analysis all on a web-accessible database for the Microbicide Development Program (MDP). The data management aims are to ensure equal access to relevant forms, databases (trial CRFs), regulatory documents, adverse event (AE) reports and iterative data/results for all program participants, including NIH Project Officers and Scientific Advisory Panel (SAP) members. Of equal importance is for the Program's team members to be able to review their own data often acquired elsewhere), which may be located at different institutions, as well as to participate in teleconferences vhere review of other Projects' results are discussed, eliminating need for multiple and unwieldy email attachments. This approach has great strengths and is pivotal to the efficiency and success of this broadly based program. Once data is reviewed and finalized, biostatistical analysis can proceed in a coordinated fashion with all associated biostatisticians working from the same locked datasets. An additional advantage of this Core is the Co-Directorship of Dr. William Cumberland, Director of the UCLA CFAR Biostatistics Core and Chair of the Biostatistics Department at UCLA. This oversight of statistical and analysis plans in all projects is coordinated to ensure cohesiveness of approach, integration of optimized methods, oversight protection and the summary capacity to assist in overall implications for one project based on findings in another project. We want to ensure that no reasonable microbicide candidate is eliminated from development (Project by Corner), that may, in fact, be prepared in an unacceptable formulation (Project by Gorbach). As all these variables can not be evaluated in a single trial, interpretative projections based on common acquisition techniques, similar populations and identical units, will be one of the strengths of this application, making the sum greater than the parts. The Core will facilitate interaction between the statistical personnel and the investigators of the different projects. Key functions will be to encourage collaborative research among the statistical personnel to solve biostatistical problems that arise during the studies. The Core Director & Co-Director will be represented on all teleconferences involving safety and data review as well as in preparation of DSMB reports with the intent that any problems encountered during this novel collaborative research will lead to new statistics methods and publications answer study questions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI060614-03
Application #
7278575
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2006-08-01
Budget End
2007-07-31
Support Year
3
Fiscal Year
2006
Total Cost
$173,488
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Chiu, Wai Kan; Brand, Rhonda M; Camp, Danielle et al. (2017) The Safety of Multiple Flexible Sigmoidoscopies with Mucosal Biopsies in Healthy Clinical Trial Participants. AIDS Res Hum Retroviruses 33:820-826
Leyva, Francisco; Fuchs, Edward J; Bakshi, Rahul et al. (2015) Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates. AIDS Res Hum Retroviruses 31:1089-97
Preza, Gloria Cuevas; Yang, Otto O; Elliott, Julie et al. (2015) T lymphocyte density and distribution in human colorectal mucosa, and inefficiency of current cell isolation protocols. PLoS One 10:e0122723
Yang, Otto O; Ibarrondo, F Javier; Price, Charles et al. (2014) Differential blood and mucosal immune responses against an HIV-1 vaccine administered via inguinal or deltoid injection. PLoS One 9:e88621
Yang, Kuo-Hsiung; Hendrix, Craig; Bumpus, Namandje et al. (2014) A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate. PLoS One 9:e106196
Richardson-Harman, Nicola; Hendrix, Craig W; Bumpus, Namandjé N et al. (2014) Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study. PLoS One 9:e111507
Gorbach, Pamina M; Pines, Heather; Javanbakht, Marjan et al. (2014) Order of orifices: sequence of condom use and ejaculation by orifice during anal intercourse among women: implications for HIV transmission. J Acquir Immune Defic Syndr 67:424-9
Pines, Heather A; Gorbach, Pamina M; Weiss, Robert E et al. (2013) Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial. AIDS Behav 17:1002-15
Leyva, Francisco J; Bakshi, Rahul P; Fuchs, Edward J et al. (2013) Isoosmolar enemas demonstrate preferential gastrointestinal distribution, safety, and acceptability compared with hyperosmolar and hypoosmolar enemas as a potential delivery vehicle for rectal microbicides. AIDS Res Hum Retroviruses 29:1487-95
Anton, Peter A; Cranston, Ross D; Kashuba, Angela et al. (2012) RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 28:1412-21

Showing the most recent 10 out of 35 publications